Loxosceles spider venom induces metalloproteinase mediated cleavage of MCP/CD46 and MHCI and induces protection against C-mediated lysis

Immunology

Volumn 107, Issue 1, 2002, Pages 102-110

  Van Den Berg, Carmen W ^a,b   Gonçalves De Andrade, Rute M ^b   Magnoli, Fabio C ^b   Marchbank, Kevin J ^a   Tambourgi, Denise V ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; MEMBRANE COFACTOR PROTEIN; METALLOPROTEINASE; PROTEINASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPIDER VENOM;

ARTICLE; AUTOIMMUNE DISEASE; CANCER; CELL LINE; CELL SURFACE; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; FLOW CYTOMETRY; HUMAN; INCUBATION TIME; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE FLUIDITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; REGULATORY MECHANISM; SPIDER; SUPERNATANT; TOXIN ANALYSIS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; COMPLEMENT INACTIVATOR PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMOLYSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; MOLECULAR SEQUENCE DATA; PHOSPHORIC DIESTER HYDROLASES; SPIDER VENOMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036379838     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01468.x     Document Type: Article

References (31)

1. Ginsburg CM, Weinberg AG. Hemolytic anemia and multi-organ failure associated with localized cutaneous lesion. J Pediatr 1988; 112:496-9.
2. Gendron BP. Loxosceles reclusa envenomation. Am J Emerg Med 1990; 8:51-4.
3. Futrell J. Loxoscelism. Am J Med Sci 1992; 304:261.
4. Bey TA, Walter FG, Lober W, Schmidt J, Spark R, Schlievert PM. Loxosceles arizonica bite associated with shock. Ann Emerg Med 1997; 30:701-3.
5. Sezerino UM, Zannin M, Coelho LK et al. A clinical and epidemiological study of Loxosceles spider envenoming in Santa Catarina. Brazil Trans R Soc Trop Med Hyg 1998; 92:546-8.
6. Tambourgi DV, Magnoli FC, Von Eickstedt VR, Benedetti ZC, Petricevich VL, da Silva WD. Incorporation of a 35-kilodalton purified protein from Loxosceles intermedia spider venom transforms human erythrocytes into activators of autologous complement alternative pathway. J Immunol 1995; 155:4459-66.
7. Tambourgi DV, Magnoli FC, van den Berg CW, Morgan BP, de Araujo PS, Alves EW, Da Silva WD. Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and complement-dependent hemolysis. Biochem Biophys Res Commun 1998; 251:366-73.
8. Tambourgi DV, Petricevich VL, Magnoli FC, Assaf SL, Jancar S, Dias Da Silva W. Endotoxemic-like shock induced by Loxosceles spider venoms: pathological changes and putative cytokine mediators. Toxicon 1998; 36:391-403.
9. Tambourgi DV, Morgan BP, de Andrade RM, Magnoli FC, van den Berg CW. Loxosceles intermedia spider envenomation induces activation of an endogenous metalloproteinase, resulting in cleavage of glycophorins from the erythrocyte surface and facilitating complement-mediated lysis. Blood 2000; 95:683-91.
10. Kiessling F, Kartenbeck J, Haller C. Cell-cell contacts in the human cell line ECV304 exhibit both endothelial and epithelial characteristics. Cell Tissue Res 1999; 297:131-40.
11. Brown J, Reading SJ, Jones S et al. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 2000; 80:37-45.
12. Suda K, Rothen-RutishauSeries B, Gunthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 2001; 37:505-14.
13. Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW, Morgan BP. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 1997; 158:1692-702.
14. van den Berg CW, Rix C, Hanna SM, Perez de la Lastra JM, Morgan BP. Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells. Transplantation 2000; 70:667-73.
15. Bucherl W. Biology and venoms of the most important South American spiders of the genera Phoneutria, Loxosceles, Lycosa, and Latrodectus. Am Zool 1969; 9:157-9.
16. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170:637-54.
17. Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA, Atkinson JP. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 1991; 174:93-102.
18. Charreau B, Cassard A, Tesson L et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994; 58:1222-9.
19. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 1999; 36:261-8.
20. Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999; 878:442-52.
21. Turner AJ, Hooper NM. Role for ADAM-family proteinases as membrane protein secretases. Biochem Soc Trans 1999; 27:255-9.
22. Mullberg J, Althoff K, Jostock T, Rose-John S. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 2000; 11:27-38.
23. Yamamoto S, Higuchi Y, Yoshiyama K, Shimizu E, Kataoka M, Hijiya N, Matsuura K. ADAM family proteins in the immune system. Immunol Today 1999; 20:278-84.
24. Jensen TS, Bjorge L, Wollen AL, Ulstein M. Identification of the complement regulatory proteins CD46, CD55, and CD59 in human fallopian tube, endometrium, and cervical mucosa and secretion. Am J Reprod Immunol 1995; 34:1-9.
25. Seya T, Hara T, Iwata K et al. Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera. Int Immunol 1995; 7:727-36.
26. Kawano M, Seya T, Koni I, Mabuchi H. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 116:542-6.
27. Shoji T, Nakanishi I, Kunitou K et al. Urine levels of CD46 (membrane cofactor protein) are increased in patients with glomerular diseases. Clin Immunol 2000; 95:163-9.
28. Soldan SS, Fogdell-Hahn A, Brennan MB et al. Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann Neurol 2001; 50:486-93.
29. Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur J Immunol 1996; 26:578-85.
30. Demaria S, Bushkin Y. Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. Hum Immunol 2000; 61:1332-8.
31. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36:929-39.